Rain On­col­o­gy's stock dives af­ter tu­mor treat­ment fails a PhI­II tri­al

Rain On­col­o­gy’s treat­ment for ded­if­fer­en­ti­at­ed li­posar­co­ma failed a Phase III clin­i­cal tri­al, rais­ing ques­tions about what’s next for the Bay Area biotech’s lead can­di­date. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER